Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation

Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation

<p><strong>Background</strong></p> <p>The TWO Study (Transplantation Without Overimmunosuppression) aimed to investigate a novel approach to regulatory T-cell (Treg) therapy in renal transplant patients, using a delayed infusion protocol at 6 mo posttransplant to promot...

Descripció completa

Dades bibliogràfiques
Autors principals:	Brook, MO, Hennessy, C, Hester, J, Hammad, S, Alzhrani, A, Rombach, I, Dutton, S, Lombardi, G, Wood, KJ, Friend, P, Harden, PN, Issa, F
Format:	Journal article
Idioma:	English
Publicat:	Wolters Kluwer 2024

Ítems similars

Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients
per: Brook, MO, et al.
Publicat: (2022)

Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
per: Muthusamy, A, et al.
Publicat: (2008)

Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy.
per: Hester, J, et al.
Publicat: (2011)

Steroid-free immunosuppression in pancreas transplantation using Alemtuzumab induction
per: Muthusamy, A, et al.
Publicat: (2007)

Feasibility, long‐term safety and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients
per: Harden, PN, et al.
Publicat: (2020)

Chimeric antigen receptors and regulatory T cells: the potential for HLA-specific immunosuppression in transplantation
per: Wright, S, et al.
Publicat: (2021)

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
per: Flechner, S, et al.
Publicat: (2005)

Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
per: Trzonkowski, P, et al.
Publicat: (2008)

Alemtuzumab: right drug, right dose?
per: Haynes, R, et al.
Publicat: (2011)

Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.
per: Plata-Munoz, J, et al.
Publicat: (2009)

ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
per: Muthusamy, A, et al.
Publicat: (2011)

Dampened inflammatory signalling and myeloid-derived suppressor-like cell accumulation reduces circulating monocytic HLA-DR density and may associate with malignancy risk in long-term renal transplant recipients
per: Bottomley, MJ, et al.
Publicat: (2022)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
per: Haynes, R, et al.
Publicat: (2014)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
per: Haynes, R, et al.
Publicat: (2014)

Expanded criteria donors in pancreas transplantation: The Oxford experience
per: Muthusamy, A, et al.
Publicat: (2009)

Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.
per: Sutherland, A, et al.
Publicat: (2014)

B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naive B cells.
per: Heidt, S, et al.
Publicat: (2012)

B cell repopulation after alemtuzumab induction - Transient increase in transitional B cells and long-term dominance of naïve B cells
per: Heidt, S, et al.
Publicat: (2012)

Alemtuzumab induction and steroid free immunosupprssion in pancreas transplantation.
per: Muthusamy, A, et al.
Publicat: (2007)

Regulatory cell therapy in kidney transplantation (The ONE Study): A harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials
per: Sawitzki, B, et al.
Publicat: (2020)

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
per: Haynes, R, et al.
Publicat: (2014)

Systematic reviews of alemtuzumab in renal transplantation.
per: O'Callaghan, J, et al.
Publicat: (2013)

Systematic reviews of alemtuzumab in renal transplantation
per: O'Callaghan, J, et al.
Publicat: (2013)

Monoclonal antibodies for immunosuppression.
per: Waldmann, H, et al.
Publicat: (1988)

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
per: Mead, A, et al.
Publicat: (2010)

Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use
per: Alzhrani, A, et al.
Publicat: (2020)

Towards regulatory cellular therapies in solid organ transplantation
per: Bottomley, MJ, et al.
Publicat: (2021)

THE USE OF MONOCLONAL ANTILYMPHOCYTE ANTIBODIES IN CLINICAL IMMUNOSUPPRESSION
per: Friend, P, et al.
Publicat: (1985)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
per: Watson, C, et al.
Publicat: (2004)

Anti-glomerular basement membrane disease after alemtuzumab.
per: Clatworthy, MR, et al.
Publicat: (2008)

Immunosuppression and cancer.
per: Kinlen, L
Publicat: (1992)

The new immunosuppression.
per: Waldmann, H
Publicat: (2003)

Malignancy and immunosuppression.
per: Kinlen, L
Publicat: (1972)

A GMP protocol for the manufacture of Tregs for clinical application
per: O'Neil, A, et al.
Publicat: (2022)

Immune monitoring for advanced cell therapy trials in transplantation: which assays and when?
per: Stark, HL, et al.
Publicat: (2021)

Separation of monoclonal antibody alemtuzumab monomer and dimers using ultrafiltration.
per: Wan, Y, et al.
Publicat: (2005)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
per: Clatworthy, MR, et al.
Publicat: (2009)

LIVING DONOR RENAL TRANSPLANTATION IN DONORS WITH INCIDENTAL NEPHROLITHIASIS
per: Patel, N, et al.
Publicat: (2011)

New trends in immunosuppression.
per: Cobbold, S
Publicat: (2005)

Therapeutic immunosuppression of T cells.
per: Waldmann, H, et al.
Publicat: (1992)